Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Luteolin + dexamethasone is a combination of two agents—luteolin, a naturally occurring flavonoid with anti-inflammatory and antioxidant properties, and dexamethasone, a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive effects. This combination has been studied in preclinical models for its synergistic effects in reducing inflammation, oxidative stress, and tissue damage. In particular, low-dose dexamethasone combined with luteolin has demonstrated improved recovery after myocardial infarction by activating the Keap1/Nrf2/HO-1 antioxidative pathway, leading to reduced reactive oxygen species (ROS) production and pro-inflammatory cytokines while enhancing antioxidative enzyme expression[1][2]. Luteolin itself also modulates multiple inflammatory pathways (including NF-κB and MAPK), enhances antioxidant defenses, and may interact with GABAA receptors to provide neuroprotective effects[4][6]. The combination is experimental; it is not an approved pharmaceutical product but rather an investigational pairing explored for potential cardioprotective or anti-inflammatory benefits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on luteolin + dexamethasone.